Compare McKesson Corporation (MCK) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs US Bancorp — how do they compare? McKesson Corporation trades at $899.06 (market cap $102.58B), while US Bancorp trades at $64.51 (market cap $100.01B). The key difference: McKesson Corporation and US Bancorp are close in size by market cap, and US Bancorp pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| MCK | USB | |
|---|---|---|
Market Cap | $102.58B | $100.01B |
Sector | Health | Financials |
52-Week High | $995.69 | $64.47 |
52-Week Low | $659.01 | $44.56 |
Enterprise Value | $109.12B | — |
Dividend Yield | 0.43% | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
U.S. Bancorp (USB) trades at $63.94, up 0.2% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $70.27. The stock shows strong fundamentals with a P/E of 12.76, net income margin of 27.61%, and three consecutive quarterly EPS beats. Recent news highlights institutional buying and upbeat Q2 2026 results, though RSI levels suggest potential overbought conditions near-term.
Outlook is positive with earnings growth and dividend stability, but risks include interest rate sensitivity and competitive pressures. Upside potential exists if the company maintains its profit trajectory, supported by analyst buy ratings. Investors should monitor debt levels and economic shifts that could impact banking sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
